Icagen (ICGN)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS
*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

4222 EMPEROR BLVD DURHAM, NC 27703

Focuses on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. The company has programs involving drugs designed to treat sickle cell anemia, epilepsy, dementia and other diseases.

View SEC Filings from ICGN instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
No data found for this quarter.
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ICGN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ICGN BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

KRAFTE DOUGLAS CHIEF SCIENTIFIC OFFICER

  • Officer
0 2016-02-25 0

OLUKOTUN ADEOYE Y

  • Director
No longer subject to file 2011-10-27 0

PFIZER INC

ECLIPSE ACQUISITION CORP.

  • 10% Owner
100 2011-10-27 0

GIORDANO DOUGLAS E.

  • Director
0 2011-09-22 0

SUPRAN BRYAN

  • Director
0 2011-09-22 0

ROCHE WILLIAM G.

  • Director
0 2011-09-22 0

MCKERNAN RUTH

  • Director
0 2011-09-22 0

WAGONER KAY PRESIDENT AND CEO

  • Officer
  • Director
0 2011-09-14 0

KATZ RICHARD D EX VP, FIN & CORP, CFO & TREAS

  • Officer
0 2011-09-14 0

LAMOTTE ANDRE

  • Director
No longer subject to file 2011-09-14 0

MORRISON RICHARD G

  • Director
No longer subject to file 2011-09-14 0

SIMONETTI MARTIN A

  • Director
0 2011-09-14 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BVF INVESTMENTS LLC

BVF INC/IL

LAMPERT MARK N

  • 10% Owner
  • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
980,200 2011-09-07 0

SANDERS CHARLES A

  • Director
0 2011-09-02 0

PFIZER INC

  • 10% Owner
5,684,060 2011-09-02 0

ECLIPSE ACQUISITION CORP.

  • 10% Owner
4,617,045 2011-09-02 0

EVNIN ANTHONY B

  • Director
7,910 2011-09-01 0

NEW LEAF VENTURES II, L.P.

NEW LEAF VENTURE ASSOCIATES II, L.P.

NEW LEAF VENTURE MANAGEMENT II, L.L.C.

CHAMBON PHILIPPE O.

NIEDEL JAMES

LATHI VIJAY K

DELAGARDELLE JEANI

HUNT RONALD

AKKARAJU SRINIVAS

  • MEMBER OF 10% OWNER GROUPMEMBER OF 10% OWNER GROUPMEMBER OF 10% OWNER GROUPMEMBER OF 10% OWNER GROUPMEMBER OF 10% OWNER GROUPMEMBER OF 10% OWNER GROUPMEMBER OF 10% OWNER GROUPMEMBER OF 10% OWNER GROUPMEMBER OF 10% OWNER GROUP
200,500 2011-07-28 0

MERLIN BIOMED PRIVATE EQUITY ADVISORS, L.L.C.

SEMON DOMINIQUE

  • 10% Owner
750,000 2011-05-18 0

HETHERINGTON SETH V SR. VP, CLIN. & REG. AFFAIRS

  • Officer
269,611 2010-08-17 0

GILLINGS DENNIS B PH D

  • Director
1,682,509 2009-06-03 0

GRAY EDWARD P SR VP, IP, CH PAT COUNSEL, SEC

  • Officer
29,420 2009-02-01 0

WALKER REID S

SMITH G STACY

WALKER PATRICK P

WS CAPITAL LLC

WS CAPITAL MANAGEMENT LP

WSV MANAGEMENT L L C

WS VENTURES MANAGEMENT L P

  • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
No longer subject to file 2008-01-29 0

WALKER PATRICK P

WALKER REID S

SMITH G STACY

BECKER STEVEN R

WS CAPITAL LLC

WS CAPITAL MANAGEMENT LP

WSV MANAGEMENT L L C

WS VENTURES MANAGEMENT L P

  • 10% Owner
2,807,063 2008-01-10 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments